Literature DB >> 17456059

The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma.

Sverker Hasselblom1, Margret Sigurdadottir, Ulrika Hansson, Herman Nilsson-Ehle, Börje Ridell, Per-Ola Andersson.   

Abstract

The prognostic significance of tumour-infiltrating lymphocytes (TILs) in patients with diffuse large B-cell lymphoma (DLBCL) remains controversial. Furthermore, the possible impact of regulatory T cells (T(regs)) on survival in DLBCL is still unknown. We performed a retrospective study on the immunohistochemical expression of cytotoxic cells and T(regs), and their correlation with survival in 195 DLBCL patients. Patients with a small number of cytotoxic T-cell intracytoplasmic antigen-1 (TIA-1)+ T cells (< or =260 cells/mm(2) tumour area; n = 52) had significantly better outcome than patients with a large number (>260 cells/mm(2); n = 143); progression-free survival (PFS) at 5 years was 67% vs. 50% (P = 0.03) and overall survival (OS) was 73% vs. 57% (P = 0.03). In multivariate analysis, the low TIA-1+ group still had a better PFS (relative risk 0.75, 95% confidence interval 0.31-0.99; P = 0.05). The number of forkhead box protein 3 (FOXP3)+ T(regs) had no influence on PFS (P = 0.89) or OS (P = 0.75). These results suggest that immunohistochemical analysis of cytotoxic T cells at time of diagnosis could provide additional prognostic information. The lack of correlation between the number of FOXP3+ cells and survival could possibly indicate that tumour-infiltrating T(regs) are of less clinical importance in DLBCL. However, these findings need to be explored in functional studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17456059     DOI: 10.1111/j.1365-2141.2007.06593.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  19 in total

1.  Stromal immune infiltration in HIV-related diffuse large B-cell lymphoma is associated with HIV disease history and patient survival.

Authors:  Chun Chao; Lanfang Xu; Michael J Silverberg; Otoniel Martínez-Maza; Lie-Hong Chen; Brandon Castor; Donald I Abrams; Hongbin D Zha; Reina Haque; Jonathan Said
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177

2.  Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma.

Authors:  Matthew J Ahearne; Kaljit Bhuller; Roger Hew; Hazem Ibrahim; Kikkeri Naresh; Simon D Wagner
Journal:  Virchows Arch       Date:  2014-07-11       Impact factor: 4.064

3.  Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP.

Authors:  Rita Coutinho; Andrew J Clear; Emanuele Mazzola; Andrew Owen; Paul Greaves; Andrew Wilson; Janet Matthews; Abigail Lee; Rute Alvarez; Maria Gomes da Silva; José Cabeçadas; Donna Neuberg; Maria Calaminici; John G Gribben
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

4.  Natural killer cell subsets and natural killer-like T-cell populations in benign and neoplastic B-cell proliferations vary based on clinicopathologic features.

Authors:  Sarah E Gibson; Steven H Swerdlow; Raymond E Felgar
Journal:  Hum Pathol       Date:  2011-02-02       Impact factor: 3.466

Review 5.  Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Authors:  Fabienne McClanahan; Thomas G Sharp; John G Gribben
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

Review 6.  Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.

Authors:  Ruifang Sun; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2016-08-01       Impact factor: 7.842

7.  The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.

Authors:  Hajnalka Rajnai; Fenna H Heyning; Lianne Koens; Anna Sebestyén; Hajnalka Andrikovics; Pancras C W Hogendoorn; András Matolcsy; Ágota Szepesi
Journal:  Virchows Arch       Date:  2013-12-04       Impact factor: 4.064

8.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

9.  Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.

Authors:  Tianqi Xu; Jia Chai; Kaijing Wang; Qingge Jia; Yixiong Liu; Yingmei Wang; Junpeng Xu; Kangjie Yu; Danhui Zhao; Jing Ma; Linni Fan; Qingguo Yan; Shuangping Guo; Gang Chen; Qiongrong Chen; Hualiang Xiao; Fang Liu; Chubo Qi; Rong Liang; Mingyang Li; Zhe Wang
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

10.  Lenalidomide in diffuse large B-cell lymphoma.

Authors:  Catherine Thieblemont; Marie-Hélène Delfau-Larue; Bertrand Coiffier
Journal:  Adv Hematol       Date:  2012-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.